MEmbranous Nephropathy Trial Of Rituximab

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

130

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

October 1, 2017

Study Completion Date

October 1, 2017

Conditions
Idiopathic Membranous Nephropathy
Interventions
DRUG

Rituximab

1000 mg, I.V. on Days 1 and 15 and will be retreated at month 6 independent of cluster of differentiation (CD) 19+ B cell count

DRUG

Cyclosporine

Patients randomized to the Cyclosporine arm will be started at a dose of (CsA = 3.5 mg/kg/day p.o. divided into 2 doses for 12 months). Target trough CsA blood levels, as determined in whole blood by High Performance Liquid Chromatography (HPLC), are 125 to 175 ng/ml. A persistent and otherwise unexplained increase in serum creatinine \>30% would prompt an approximate 25% dose reduction of CSA, aiming for a corresponding 25% reduction in CSA trough level. If with this dose reduction the creatinine does not return to within 30% of baseline levels within 3 weeks, then a second dose reduction of approximately 25% with similar reduction in CSA trough level will be used. If the creatinine does not fall to baseline values with this second dose reduction, the drug will be discontinued. At the end of 12 months, Cyclosporine will be tapered by 1/3 of the maintenance dose monthly and hence discontinued after 3 months.

Trial Locations (21)

10016

New York University, New York

10032

Columbia University Medical Center, New York

32224

Mayo Clinic Jacksonville, Jacksonville

33136

University of Miami Hospital and Clinics, Miami

35294

University of Alabama at Birmingham, Birmingham

39216

University of Mississippi Medical Center, Jackson

43210

Ohio State University, Columbus

44109

MetroHealth System (Case Western Reserve University), Cleveland

44195

Cleveland Clinic, Cleveland

48109

University of Michigan, Ann Arbor

53226

Medical College of Wisconsin, Froedtert Hospital, Milwaukee

55905

Mayo Clinic Rochester, Rochester

63110

Washington University School of Medicine, St Louis

66160

University of Kansas Medical Center, Kansas City

85054

Mayo Clinic Scottsdale, Scottsdale

85724

University of Arizona, Tucson, Tucson

94304

Stanford University, San Francisco

98195

University of Washington Medical Center, Seattle

V6Z1Y6

St. Paul's Hospital, Providence Health Care, Vancouver

M5G2C4

Toronto General Hospital, Toronto

G1R 2J6

Centre hospitalier universitaire de Quebec - Hotel-Dieu de Quebec, Québec

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Columbia University

OTHER

collaborator

University of British Columbia

OTHER

collaborator

Ohio State University

OTHER

collaborator

Stanford University

OTHER

collaborator

University of Washington

OTHER

collaborator

University of Michigan

OTHER

collaborator

University of Alabama at Birmingham

OTHER

collaborator

Case Western Reserve University

OTHER

collaborator

The Cleveland Clinic

OTHER

collaborator

University of Kansas Medical Center

OTHER

collaborator

University of Manchester

OTHER

collaborator

University Health Network, Toronto

OTHER

collaborator

University of Toronto

OTHER

collaborator

CHU de Quebec-Universite Laval

OTHER

collaborator

Washington University School of Medicine

OTHER

collaborator

Florida International University

OTHER

collaborator

University of Mississippi Medical Center

OTHER

collaborator

NYU Langone Health

OTHER

collaborator

Medical College of Wisconsin

OTHER

collaborator

University of Arizona

OTHER

collaborator

Sunnybrook Health Sciences Centre

OTHER

collaborator

Applied Health Research Centre

OTHER

collaborator

Fulk Family Foundation

UNKNOWN

lead

Mayo Clinic

OTHER